Launch marks major expansion of company’s medicinal cannabis offering, alongside existing expertise in cultivation and delivery of cannabis flowers to partners
Capabilities include supply of APIs and medicinal finished dosage forms, such as THC and standardized cannabis extracts
Madrid, Spain, 07 March 2024: Linneo Health, a global leader in the research, cultivation and supply of cannabis to improve human health and wellbeing, today announces the launch of its industrial cannabis derivatives portfolio.
The Company has also completed its first shipment of products from the new portfolio to customers in Europe, including Germany, one of Europe’s largest and fastest growing medicinal cannabis markets.
Linneo’s industrial derivative products portfolio expands the Company’s medicinal cannabis offering alongside its existing expertise in the cultivation and delivery of Good Manufacturing Practice (EU-GMP) certified medicinal cannabis flowers.
The portfolio, which includes active pharmaceutical ingredients (APIs) and medicinal finished dosage forms, such as tetrahydrocannabinol (THC) and standardised cannabis extracts, is now widely available to global medicinal cannabis markets. Linneo’s offering includes pure and dronabinol DAC, which can be supplied by bulk shipment and in pre-filled syringes to customers, and full spectrum oils available in various concentrations as needed, to suit the specific therapeutic needs of patients.
Linneo’s portfolio of products are produced under EU-GMP certified industrial processes and derived from the Company’s biomass of flowers, cultivated according to good agricultural and collecting practices (GACP). These guarantee the highest quality final industrial product and ensure, the highest pharmaceutical grade manufacturing standards are achieved to comply with regulatory standards around the world.
Don Bellamy, Chief Executive Officer at Linneo Health, commented: “Linneo’s expanded medicinal cannabis portfolio underscores our dedication to providing our partners with diverse, high-quality medicinal cannabis solutions tailored to their unique needs and ultimately for the benefit of patients in the treatments of their diseases. As a leader in this industry, we remain steadfast in our mission to deliver reliable, safe, and effective options that help our partners empower patients to manage their health with confidence.”
– ENDS –
Enquiries:
Linneo Health
Don Bellamy, CEO Tel: +34 91 700 20 90
ICR Consilium
Amber Fennell / David Daley / Kris Lam Tel: +44 (0) 20 3709 5700
Linneo Health is a Europe based, global leader in the research, EU-GMP certified manufacture and supply of medicinal cannabis flowers, extracts and products to pharmaceutical partners developing innovative cannabis-based therapies for patients in need. The world’s only vertically integrated medicinal cannabis supplier, no other company has Linneo’s 90-year heritage in the manufacturing and movement of controlled substances. Linneo is optimally positioned to address the needs of its customers through every stage of product development, regulation and handling.
Linneo Health is setting the benchmark for standards and customer service in medicinal cannabis. Through ongoing investment in one of the most advanced quality control laboratories in Europe, and by applying industry-leading cultivation techniques, Linneo is the trusted partner to address the needs of customers today and, with significant expansion capabilities, the demands of tomorrow. With an unrivalled focus on quality and driven by the firm belief that people around the world deserve to be treated with cannabis medicine of the highest standard, Linneo brings cutting edge innovation in medicinal cannabis to partners, to deliver better patient outcomes and improve lives. www.linneohealth.com
